Advertisement

Endocrine Effects of Neuroleptics

  • F. G. Sulman
  • Y. Givant
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 55 / 1)

Abstract

Psychotherapeutic drugs have been reported to interfere with a variety of endocrine functions, including lactation in man and experimental animals. In 1954, Wilkins reported the development of gynecomastia following treatment with Rauwolfia alkaloids. Winnik and Tennenbaum showed in 1955 that treatment with chlorpromazine (Largactil, Thorazine or Megaphen) could lead to milk secretion in women. Sulman and Winnik, and Winnik and Sulman, studying this problem in 1956, described spontaneous lactation in women and animals, and other endocrine disturbances after treatment with chlorpromazine. Our experience with psychopharmaca was confirmed and lactation was reported to occur in women who received either reserpine or chlorpromazine (Marshall and Leiberman, 1956, and Platt and Sears, 1956). Animal experiments also confirmed our findings, treatment with reserpine resulted in milk secretion in rabbits (Meites, 1957, Sawyer, 1957). Administration of various other phenothiazine derivatives also produced mammary differentiation and milk secretion in rats (Sulman et al., 1970). These endocrine disturbances were presumed to result from the action of major tranquilizers on the reticular formation and hypothalamic regions which regulate the releasing and inhibiting functions of the pituitary. The name “hypothalamic tranquilizers” has, therefore, been given to those agents which cause endocrine disturbances such as lactation or suppression of gonadotropins and STH.

Keywords

Prolactin Secretion Prolactin Release Endocrine Disturbance Milk Secretion Phenothiazine Derivative 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbrevations

ACTH

Adrenocorticotropic hormone

ADH

Antidiuretic hormone, vasopressin

FSH

Follicle stimulating hormone

ICSH

Interstitial stimulating hormone (in the male)

LH

Luteinizing hormone (in the female)

LTH

Luteotropic hormone, lactotropic hormone (prolactin)

MAO

Monoamine oxidase

MSH

Melanophore stimulating hormone (intermedin)

PIF

Prolactin inhibiting factor

PRF

Prolactin releasing factor

STH

Somatotropic hormone, growth hormone

TSH

Thyrotropic hormone

UCH

Uterus contracting hormone (oxytocin)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Armstrong, B., Stevens, N., Doll, R.: Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women. Lancet 2, 672–675 (1974)PubMedCrossRefGoogle Scholar
  2. Assael, M., Gabai, F., Winnik, H.Z., Khazan, N., Sulman, F.G.: Recession of exophthalmos after massive doses of reserpine. Lancet 1, 499–500 (1960a)CrossRefGoogle Scholar
  3. Assael, M., Sulman, F.G., Winnik, H.Z.: Clinical and endocrinological effects of hydroxyzine. J. Ment. Sci. 106, 1027–1030 (1960b)PubMedGoogle Scholar
  4. Bateson, M.C., Browning, M.C.K., Maconnachie, A.: Galactorrhoea with Cimetidine. Lancet 2, 247–248 (1977)PubMedCrossRefGoogle Scholar
  5. Ben-David, M.: The role of the ovaries in perphenazine-induced lactation. J. Endocrinol. 41, 377–385 (1968)PubMedCrossRefGoogle Scholar
  6. Ben-David, M., Dikstein, S., Sulman, F.G.: Production of lactation by non-sedative phenothiazine derivatives. Proc. Soc. Exp. Biol. Med. 118, 265–270 (1965)PubMedGoogle Scholar
  7. Boston Collaborative Drug Surveillance Program: Reserpine and breast cancer. Lancet 2, 669–671 (1974)Google Scholar
  8. Calaf, J.: Prolactin release. Proc. Int. Symp. Human Prolactin. Brussels: Exc. Med. Int. Congr. Ser. 308, 221–222 (1973)Google Scholar
  9. Danon, A., Dikstein, S., Sulman, F.G.: Stimulation of prolactin secretion by perphenazine in pituitary-hypothalamus organ culture. Proc. Soc. Exp. Biol. Med. 114, 366–368 (1963)PubMedGoogle Scholar
  10. Debeljuk, L., Dashal, H., Rozados, R., Guitelman, A.: Effect of sulpiride on prolactin release by rat pituitaries in vitro. Experientia 30, 1355–1356 (1974)PubMedCrossRefGoogle Scholar
  11. Del Pozo, E., Flueckiger, E.: Prolactin inhibition: experimental and clinical studies. Proc. Int. Symp. Human Prolactin. Brussels: Exc. Med. Int. Congr. Ser. 308, 291–301 (1973)Google Scholar
  12. De Wied, D.: Chlorpromazine and endocrine function. Pharmacol. Rev. 19, 251–288 (1967)Google Scholar
  13. Dickerman, S., Kledzik, G., Gelato, M., Chen, H.J., Meites, J.: Effect of haloperidol on serum and pituitary prolactin, LH and FSH, and Hypothalamic PIF and LRF. Neuroendocrinology 15, 10–20 (1974)PubMedCrossRefGoogle Scholar
  14. Dikstein, S., Sulman, F.G.: Drugs acting on the hypothalamus-pituitary axis. Obstet. & Gyncl. Survey 21, 531–547(1966)CrossRefGoogle Scholar
  15. Everett, J.W., Radford, H.M., Holsinger, J.: Hormonal steroids. In: Steroids. Martini, L., Pecil, A. (eds.). New York: Academic Press 1964, Vol. 1, pp. 235–246Google Scholar
  16. Givant, Y., Sulman, F.G.: Endocrine effects of psychotherapeutic drugs. In: Psychotherapeutic Drugs. Usdin, E., Forrest, I.S. (eds.). New York: Marcel Dekker 1976, pp. 387–436Google Scholar
  17. Hedge, G.A., Smelik, P.G.: Corticotropin release: Inhibition by intrahypothalamic implantation of atropine. Science 159, 891–892 (1968)PubMedCrossRefGoogle Scholar
  18. Heinonen, O.P., Shapiro, S., Tuominen, L., Turunen, M.I.: Reserpine use in relation to breast cancer. Lancet 2, 675–677 (1974)PubMedCrossRefGoogle Scholar
  19. Horrobin, D.F.: Prolactin Physiology and Clinical Significance. London: Medical and Technical Publishing Co. MTP 1973Google Scholar
  20. Horrobin, D.F.: In: Prolactin 1974. Horrobin, D.F. (ed.). London: Medical and Technical Publishing Co. MTP 1974Google Scholar
  21. Janssen, P.A.J.: The pharmacology of haloperidol. Int. J. Neuropsychiatry 3 [Suppl. 1], 10–18 (1967)PubMedGoogle Scholar
  22. Janssen, P.A.J., Van den Westeringh, C., Jageneau, A.H.M., Demoen, P.J.A., Hermans, B.K.F., Van Daele, G.H.P., Schellekens, K.H.L., Van der Eycken, G.A.M., Niemegeers, C.J.E.: Chemistry and pharmacology of CNS depressants related to 4-(4-hydroxy-4-phenylpiperidino) butyrophenone. Part I: Synthesis and screening data in mice. J. Med. Pharm. Chem. 1, 281–297 (1959)PubMedCrossRefGoogle Scholar
  23. Khazan, N., Sulman, F.G.: Melanophore-dispersing activity of reserpine in Rana frogs. Proc. Soc. Exp. Biol. Med. 107, 282–284 (1961)PubMedGoogle Scholar
  24. Khazan, N., Sulman, F.G., Winnik, H.Z.: Activity of pituitary-adrenal cortex axis during acute and chronic reserpine treatment. Proc. Soc. Exp. Biol. Med. 106, 579–581 (1961)PubMedGoogle Scholar
  25. Khazan, N., Ben-David, M., Mishkinsky, J., Khazen, K., Sulman, F.G.: Dissociation between mammotropic and sedative effects of nonhormonal hypothalamic tranquilizers. Arch. Int. Pharmacodyn. Ther. 164, 258–271 (1966)Google Scholar
  26. Khazen, K., Mishkinsky, J., Ben-David, M., Sulman, F.G.: Lactogenic effect of phenothiazinelike drugs. Arch. Int. Pharmacodyn. Ther. 174, 428–441 (1968)PubMedGoogle Scholar
  27. Kulcsar, S., Polishuk, W., Rubin, L.: Aspects endocriniens du traitement à la chlorpromazine. Presse Méd. 65, 1288–1290 (1957)PubMedGoogle Scholar
  28. Laborit, H., Huguenard, P.: L’hibernation artificielle par moyens pharmacodynamiques et physiques. Presse Méd. 64, 1329–1331 (1951)Google Scholar
  29. Lazarus, J.H., Bennie, E.H.: Effect of lithium on thyroid function in man. Acta Endocrinol. 70, 266–272 (1972)PubMedGoogle Scholar
  30. L’Hermite, M., Delroye, P., Nokin, J., Vekemans, M., Robyn, C.: IV th Tenovus Workshop on Prolactin. Cardiff: Alpha Omega Alpha 1972Google Scholar
  31. Locker, D., Superstine, E., Sulman, F.G.: The mechanism of the Push and Pull Principle. VIII: Endocrine effects of thalidomide and its analogues. Arch. Int. Pharmacodyn. Ther. 194, 39–55 (1971)PubMedGoogle Scholar
  32. Marshall, W.K., Leiberman, D.M.: A rare complication of chlorpromazine treatment. Lancet 1, 162–163 (1956)CrossRefGoogle Scholar
  33. Mashiter, K., Adams, E., Beard, M., Holley, A.: Bromocriptine inhibits prolactin and growthhormone release by human pituitary tumours in culture. Lancet 2, 197–198 (1977)PubMedCrossRefGoogle Scholar
  34. Meites, J.: Induction of lactation in rabbits with reserpine. Proc. Soc. Exp. Biol. Med. 96, 728–730 (1957)PubMedGoogle Scholar
  35. Meites, J.: Neurohumoral and pharmacological control of prolactin secretion. Scientific group on the physiology of lactation. Geneva: WHO 1963Google Scholar
  36. Meites, J., Nicoll, C.S., Talwalker, P.K.: Effect of reserpine and serotonin on milk secretion and mammary growth in the rat. Proc. Soc. Exp. Biol. Med. 101, 563–565 (1959)PubMedGoogle Scholar
  37. Mishkinsky, J., Khazen, K., Givant, Y., Dikstein, S., Sulman, F.G.: Mammotropic and neuroleptic effects of butyrophenones in the rat. Arch. Int. Pharmacodyn. Ther. 179, 94–105 (1969)PubMedGoogle Scholar
  38. Moerck, H.J., Magelund, G.: Lancet 1, 1344–1345 (1979)PubMedCrossRefGoogle Scholar
  39. Platt, R., Sears, H.T.N.: Reserpine in severe hypertension. Lancet 1, 401–403 (1956)CrossRefGoogle Scholar
  40. Sawyer, C.H.: Induction of lactation in the rabbit with reserpine. Anat. Rec. 127, 362–363 (1957)Google Scholar
  41. Schou, M., Amdisen, A., Jensen, S.E., Olsen, T.: Occurrence of goitre during lithium treatment. Br. Med. J. 3, 710–713 (1968)PubMedCrossRefGoogle Scholar
  42. Shani (Mishkinsky), J., Givant, Y., Sulman, F.G., Eylath, U., Eckstein, B.: Competition of phenothiazines with oestradiol for oestradiol receptors in rat brain. Neuroendocrinology 8, 307–316 (1971)PubMedCrossRefGoogle Scholar
  43. Shani, J., Givant, Y., Goldhaber, G., Sulman, F.G.: Multi-phasic prolactin release in mammary development in virgin rats after prolonged treatment with perphenazine or perphenazine sulfoxide. J. Endocrinol. 70, 311–312 (1976)PubMedCrossRefGoogle Scholar
  44. Sulman, F.G.: Experiments on the mechanism of the “Push and Pull” principle. J. Endocrinol. 14, 27–28 (1956)Google Scholar
  45. Sulman, F.G.: The mechanism of the “Push and Pull” principle. II. Endocrine effects of hypothalamus depressants of the phenothiazine group. Arch. Int. Pharmacodyn. Ther. 118, 298–307 (1959)PubMedGoogle Scholar
  46. Sulman, F.G.: Skin pigmentation following chlorpromazine treatment. Lancet 2, 592–593 (1964)PubMedCrossRefGoogle Scholar
  47. Sulman, F.G., Winnik, H.Z.: Hormonal effects of chlorpromazine. Lancet 1, 161–162 (1956)CrossRefGoogle Scholar
  48. Sulman, F.G., Ben-David, M., Danon, A., Dikstein, S., Givant, Y., Khazen, K., Mishkinsky-Shani, J., Nir, I., Weller, C.P.: Hypothalamic Control of Lactation. Monograph. Gross, F., Labhart, A., Mann, T., Samuels, L.T., Zander, J. (eds.). Berlin, Heidelberg, New York: Springer 1970Google Scholar
  49. Sulman, F.G., Pfeifer, Y., Superstine, E.: Adrenal medullary exhaustion from tropical winds and its management. Isr. J. Med. Sci. 8, 1022–1027 (1973)Google Scholar
  50. Sulman, F.G., Tal., E., Pfeifer, Y., Superstine, E.: Intermittent hyperthyreosis — a heat stress syndrome. Horm. Metab. Res. 7, 424–428 (1975)PubMedCrossRefGoogle Scholar
  51. Tal, E., Sulman, F.G.: Urinary thyroxine. Lancet 1, 1291–1292 (1972)PubMedCrossRefGoogle Scholar
  52. Wilkins, R.W.: Clinical usage of rauwolfia alkaloids, including reserpine (Serpasil). Ann. N.Y. Acad. Sci. 59, 36–44 (1954)PubMedCrossRefGoogle Scholar
  53. Winnik, H.Z., Sulman, F.G.: Hormonal depression due to treatment with chlorpromazine. Nature 178, 365–366 (1956)PubMedGoogle Scholar
  54. Winnik, H.Z., Tennenbaum, L.: Apparition de galactorrhée au cours du traitement de largactil. Presse Méd. 63, 1092–1093 (1955)PubMedGoogle Scholar
  55. Zor, U., Dikstein, S., Sulman, F.G.: The effect of monoamine oxidase inhibitors on growth and the rat tibia test. J. Endocrinol. 32, 36–44 (1965a)CrossRefGoogle Scholar
  56. Zor, U., Dikstein, S., Sulman, F.G.: The effect of monoamine oxidase inhibitors on growth: Mechanism of the potentiating effect on corticosteroids. J. Endocrinol. 33, 211–222 (1965b)PubMedCrossRefGoogle Scholar
  57. Zor, U., Mishkinsky, J., Sulman, F.G.: The hypoglycaemic effect of mebanazine (Actomol) and its mechanism. Biochem. Pharmacol. 14, 1059–1064 (1965c)PubMedCrossRefGoogle Scholar
  58. Zor, U., Locker, D., Schleider, M., Sulman, F.G.: Effect of monoamine oxidase inhibitor (Mebanazine) on brain glucose-6-phosphate dehydrogenase activity. Eur. J. Pharmacol. 2, 193–195 (1967 a)PubMedCrossRefGoogle Scholar
  59. Zor, U., Shore, J., Locker, D., Sulman, F.G.: Metabolic effects of monoamine oxidase inhibitors on the rat pituitary. J. Endocrinol. 39, 1–6 (1967b)PubMedCrossRefGoogle Scholar
  60. Zor, U., Locker, D., Schleider, M., Sulman, F.G.: Metabolic and enzymatic effects of monoamine oxidase inhibitors with and without hydrocortisone on the accessory sex glands of the rat. Eur. J. Pharmacol. 3, 81–83 (1968)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • F. G. Sulman
  • Y. Givant

There are no affiliations available

Personalised recommendations